Top Markets
#1 Black Phoenix Black Phoenix +356.03%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.21%
#4 Akedo Akedo +46.51%
#5 Acurast Acurast +34.08%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.76%
#7 BasedHype BasedHype +25.78%
#8 Avantis Avantis +21.64%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.54%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rank in Stocks #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Share Price
$0.02765
Last synced: 2024-12-23
Market Cap
$69.04K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Histogen Inc. (HSTO)

Category

Healthcare
Revenue for Histogen Inc. (HSTO)
Revenue in Sep 2023 TTM: $19.00K
According to Histogen Inc. latest financial reports the company's current revenue (TTM) is $19.00K. In 2021 the company made a revenue of $919.00K a decrease compared to the revenue in the year 2020 that was $2.06M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Histogen Inc. from 2011 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $19.00K -99.50%
2022 $3.77M 310.12%
2021 $919.00K -55.37%
2020 $2.06M -82.02%
2019 $11.45M -65.90%
2018 $33.59M -5.06%
2017 $35.38M 4,327.40%
2016 $799.05K 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 66,443,584.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 31,690,885.84%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 53,214,566.82%
BE